CytomX Therapeutics (CTMX) has shared an announcement.
Chris Ogden has been appointed as the new Chief Financial Officer of CytomX Therapeutics, Inc., effective June 15, 2024, following his previous role as Senior Vice President of Finance and Accounting. With no disclosed familial or transactional conflicts, Ogden’s promotion comes with a stock option to purchase 75,000 shares and a restricted stock unit for 17,500 shares under the company’s equity incentive plan. His solid track record in finance is backed by an indemnification agreement with the company, ensuring a smooth transition into his new executive role.
For a thorough assessment of CTMX stock, go to TipRanks’ Stock Analysis page.
